These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24162038)

  • 21. Self-Reported Health-Related Quality of Life of Children with Spinal Muscular Atrophy: Preliminary Insights from a Nationwide Patient Registry in Germany.
    Landfeldt E; Leibrock B; Hussong J; Thiele S; Abner S; Walter MC; Moehler E; Zemlin M; Dillmann U; Flotats-Bastardas M
    J Neuromuscul Dis; 2024; 11(1):117-128. PubMed ID: 38108360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lower incidence of deletions in the survival of motor neuron gene and the neuronal apoptosis inhibitory protein gene in children with spinal muscular atrophy from Serbia.
    Miskovic M; Lalic T; Radivojevic D; Cirkovic S; Vlahovic G; Zamurovic D; Guc-Scekic M
    Tohoku J Exp Med; 2011 Nov; 225(3):153-9. PubMed ID: 21971302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges and opportunities in clinical trials for spinal muscular atrophy.
    Hirtz D; Iannaccone S; Heemskerk J; Gwinn-Hardy K; Moxley R; Rowland LP
    Neurology; 2005 Nov; 65(9):1352-7. PubMed ID: 16275820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity.
    Harada Y; Sutomo R; Sadewa AH; Akutsu T; Takeshima Y; Wada H; Matsuo M; Nishio H
    J Neurol; 2002 Sep; 249(9):1211-9. PubMed ID: 12242541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy.
    Gusset N; Stalens C; Stumpe E; Klouvi L; Mejat A; Ouillade MC; de Lemus M
    Neuromuscul Disord; 2021 May; 31(5):419-430. PubMed ID: 33752935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings From the Cure SMA Cohort.
    Jones CC; Cook SF; Jarecki J; Belter L; Reyna SP; Staropoli J; Farwell W; Hobby K
    J Neuromuscul Dis; 2020; 7(1):33-40. PubMed ID: 31707372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex Difference in Spinal Muscular Atrophy Patients - are Males More Vulnerable?
    Sun J; Harrington MA; Porter B;
    J Neuromuscul Dis; 2023; 10(5):847-867. PubMed ID: 37393514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular genetic diagnosis and deletion analysis in Type I-III spinal muscular atrophy].
    Spiegel R; Hagmann A; Boltshauser E; Moser H
    Schweiz Med Wochenschr; 1996 May; 126(21):907-14. PubMed ID: 8693311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada.
    McMillan HJ; Gerber B; Cowling T; Khuu W; Mayer M; Wu JW; Maturi B; Klein-Panneton K; Cabalteja C; Lochmüller H
    J Neuromuscul Dis; 2021; 8(4):553-568. PubMed ID: 33749617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different molecular basis for spinal muscular atrophy in South African black patients.
    Stevens G; Yawitch T; Rodda J; Verhaart S; Krause A
    Am J Med Genet; 1999 Oct; 86(5):420-6. PubMed ID: 10508982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The First Report of Iranian Registry of Patients with Spinal Muscular Atrophy.
    Mansouri V; Heidari M; Bemanalizadeh M; Azizimalamiri R; Nafissi S; Akbari MG; Barzegar M; Moayedi AR; Badv RS; Mohamadi M; Tavasoli AR; Amirsalari S; Khajeh A; Inaloo S; Fatehi F; Hosseinpour S; Babaei M; Hosseini SA; Mahdi Hosseiny SM; Fayyazi A; Hosseini F; Toosi MB; Khosroshahi N; Ghabeli H; Biglari HN; Kakhki SK; Mirlohi SH; Bidabadi E; Mohammadi B; Omrani A; Sedighi M; Vafaee-Shahi M; Rasulinezhad M; Hoseini SM; Movahedinia M; Rezaei Z; Karimi P; Farshadmoghadam H; Anvari S; Yaghini O; Nasiri J; Zamani G; Ashrafi MR
    J Neuromuscul Dis; 2023; 10(2):211-225. PubMed ID: 36776076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spinal muscular atrophies.
    Darras BT
    Pediatr Clin North Am; 2015 Jun; 62(3):743-66. PubMed ID: 26022173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiological investigation of spinal muscular atrophy in Japan.
    Ito M; Yamauchi A; Urano M; Kato T; Matsuo M; Nakashima K; Saito K
    Brain Dev; 2022 Jan; 44(1):2-16. PubMed ID: 34452804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anesthesia and spinal muscle atrophy.
    Islander G
    Paediatr Anaesth; 2013 Sep; 23(9):804-16. PubMed ID: 23601145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of a national population-based carrier-screening program on spinal muscular atrophy births.
    Aharoni S; Nevo Y; Orenstein N; Basel-Salmon L; Ben-Shachar S; Mussaffi H; Sagi-Dain L; Cohen R; Singer A
    Neuromuscul Disord; 2020 Dec; 30(12):970-974. PubMed ID: 33218846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design.
    Finkel RS; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Shieh PB; Tizzano E; Desguerre I; Quijano-Roy S; Saito K; Droege M; Dabbous O; Khan F; Renault L; Anderson FA; Servais L
    J Neuromuscul Dis; 2020; 7(2):145-152. PubMed ID: 32039859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular genetics of spinal muscular atrophy: contribution of the NAIP gene to clinical severity.
    Akutsu T; Nishio H; Sumino K; Takeshima Y; Tsuneishi S; Wada H; Takada S; Matsuo M; Nakamura H
    Kobe J Med Sci; 2002 Apr; 48(1-2):25-31. PubMed ID: 11912351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
    Paracha N; Hudson P; Mitchell S; Sutherland CS
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):11-38. PubMed ID: 34761360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.